A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Public ClinicalTrials.gov record NCT06136559. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent central review (BICR) and (2) nemtabrutinib is superior to ibrutinib or acalabrutinib with respect to progression free survival (PFS) per iwCLL Criteria 2018 by BICR.
Study identification
- NCT ID
- NCT06136559
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,200 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 12, 2023
- Primary completion
- Sep 6, 2032
- Completion
- Sep 6, 2032
- Last update posted
- Aug 26, 2026
2023 – 2032
United States locations
- U.S. sites
- 46
- U.S. states
- 23
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USA Mitchell Cancer Institute ( Site 0014) | Mobile | Alabama | 36604 | Recruiting |
| Banner MD Anderson Cancer Center ( Site 0059) | Gilbert | Arizona | 85234 | Recruiting |
| Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051) | Phoenix | Arizona | 85006 | Recruiting |
| Arizona Oncology Associates - NAHOA ( Site 8007) | Prescott | Arizona | 86301 | Completed |
| Alta Bates Summit Medical Center ( Site 0004) | Berkeley | California | 94704 | Active, not recruiting |
| Moores Cancer Center ( Site 0003) | La Jolla | California | 92093-0698 | Recruiting |
| Care Access - South Pasadena ( Site 0070) | Pasadena | California | 91105 | Recruiting |
| Saint Joseph Hospital ( Site 0026) | Denver | Colorado | 80218 | Recruiting |
| Lutheran Medical Center ( Site 0027) | Golden | Colorado | 80401 | Recruiting |
| Intermountain Health St. Mary's Regional Hospital ( Site 0025) | Grand Junction | Colorado | 81501 | Recruiting |
| Eastern CT Hematology & Oncology Associates ( Site 0033) | Norwich | Connecticut | 06360 | Recruiting |
| Lynn Cancer Center at Boca Raton Regional Hospital ( Site 0063) | Boca Raton | Florida | 33486 | Recruiting |
| Clermont Oncology Center ( Site 0046) | Clermont | Florida | 34711 | Recruiting |
| Florida Cancer Specialists - South ( Site 7001) | Fort Myers | Florida | 33901 | Recruiting |
| Florida Cancer Specialists - East ( Site 7002) | West Palm Beach | Florida | 33401 | Recruiting |
| Saint Alphonsus Regional Medical Center ( Site 0067) | Boise | Idaho | 83706 | Recruiting |
| Parkview Research Center at Parkview Regional Medical Center ( Site 0002) | Fort Wayne | Indiana | 46845 | Recruiting |
| University of Iowa Health Care. ( Site 0017) | Iowa City | Iowa | 52242 | Recruiting |
| University of Iowa Health Care. ( Site 0057) | Waukee | Iowa | 50263 | Recruiting |
| Saint Elizabeth Healthcare ( Site 0041) | Edgewood | Kentucky | 41017 | Recruiting |
| Owensboro Medical Health System ( Site 0066) | Owensboro | Kentucky | 42303 | Recruiting |
| Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011) | Grand Rapids | Michigan | 49503 | Recruiting |
| Regions Hospital ( Site 0042) | Saint Louis Park | Minnesota | 55416 | Recruiting |
| MidAmerica Cancer Care, LLC ( Site 0043) | Kansas City | Missouri | 64132 | Recruiting |
| Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0052) | Billings | Montana | 59102 | Recruiting |
| Summit Medical Group Cancer Center ( Site 0007) | Florham Park | New Jersey | 07932 | Completed |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016) | Hackensack | New Jersey | 07601 | Recruiting |
| New York Oncology Hematology, P.C. ( Site 0069) | Albany | New York | 12208 | Recruiting |
| Roswell Park Cancer Institute ( Site 0023) | Buffalo | New York | 14263 | Recruiting |
| RPCI Oncology, PC- Northtowns ( Site 0061) | Williamsville | New York | 14221 | Recruiting |
| Carolina Oncology Specialists, PA ( Site 0054) | Charlotte | North Carolina | 28207 | Recruiting |
| Southeastern Medical Oncology Center ( Site 0049) | Goldsboro | North Carolina | 27534 | Recruiting |
| Consultants in Medical Oncology and Hematology (CMOH) ( Site 8002) | Broomall | Pennsylvania | 19008 | Recruiting |
| Cancer Care Associates Of York ( Site 0005) | York | Pennsylvania | 17403 | Recruiting |
| Tennessee Oncology-Chattanooga ( Site 0045) | Chattanooga | Tennessee | 37404 | Recruiting |
| Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031) | Nashville | Tennessee | 37203 | Recruiting |
| Texas Oncology - Central/South Texas ( Site 8008) | Austin | Texas | 78705 | Recruiting |
| The Center for Cancer and Blood Disorders ( Site 0032) | Fort Worth | Texas | 76104 | Recruiting |
| Texas Oncology - San Antonio ( Site 8006) | San Antonio | Texas | 78217 | Recruiting |
| Texas Oncology - Northeast Texas ( Site 8012) | Tyler | Texas | 75702 | Recruiting |
| University of Virginia Cancer Center ( Site 0040) | Charlottesville | Virginia | 22903 | Recruiting |
| Inova Schar Cancer Institute ( Site 0015) | Fairfax | Virginia | 22031 | Recruiting |
| Virginia Commonwealth University (VCU) Medical Center ( Site 0030) | Richmond | Virginia | 23298 | Recruiting |
| Medical Oncology Associates, PS (dba Summit Cancer Centers) ( Site 0010) | Spokane | Washington | 99208 | Recruiting |
| SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical ( Site 0048) | Madison | Wisconsin | 53715 | Recruiting |
| University Hospital and UW Health Clinics ( Site 0006) | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 155 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06136559, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06136559 live on ClinicalTrials.gov.